News | Contrast Media | July 12, 2016

ACR Manual on Contrast Media Addresses FDA Gadolinium Safety Concerns

Updated resource for radiologists guides safe, effective use of contrast media in daily practice

gadolinium, ACR Manual on Contrast Media, update, FDA safety concerns

July 12, 2016 — The updated American College of Radiology (ACR) Manual on Contrast Media contains a statement addressing the U.S. Food and Drug Administration (FDA) safety communication on use of gadolinium-based contrast agents for magnetic resonance imaging (MRI).

Gadolinium-based contrast agents are administered to approximately 30 million patients every year to improve the diagnostic accuracy of MR examinations. Researchers have found that gadolinium-based contrast agents may leave deposits in the brain, bone and other organs. “If the decision is made to use a gadolinium-based contrast agent for an MRI study for an individual patient, multiple factors need to be considered … including diagnostic efficacy, relaxivity, rate of adverse reactions, dosing/concentration and propensity to deposit in more sensitive organs, such as the brain,” notes a joint statement from the ACR and the American Society of Neuroradiology (ASNR).

“This vital guide for radiologists enhances the safe and effective use of contrast media in daily practice to ensure optimal patient care,” said Jacqueline Bello, M.D., FACR, chair of the ACR Commission on Quality and Safety. “The timely inclusion of the ACR and ASNR joint statement addresses questions posed by many radiology professionals about gadolinium-based contrast agents in the previous months,” she added.

“Reviews from radiologists show that this reference on contrast media is a practical and valuable resource in support of the millions of radiological examinations that may be assisted by intravascular contrast media annually,” said James H. Ellis, M.D., FACR, chair of the ACR Committee on Drugs and Contrast Media. He noted that the manual continues to be available for free as a frequently updated downloadable document on the ACR website.

Version 10.2 of the resource for using contrast media in diagnostic imaging includes:

  • An updated footnote in “Metformin,” concerning the FDA’s April 2016 guidance on patients who take this medication and who receive iodinated contrast media;
  • Information and new references about intra-osseous injection in “Injection of Contrast Media”; and
  • The addition of a document version history, so users may track changes from version to version.

 

Related Gadolinium Safety Concern Articles

Gadolinium May Remain in Brain after Contrast MRI

MRIs During Pregnancy Are Safe, But Gadolinium Scans May Increase Risk to Fetus

Study Finds No Association Between Gadolinium Contrast and Nervous System Disorder

Even High Doses of Gadolinium-Based Contrast Agents Doesn't Cause NSF

 

For more information: www.acr.org

Related Content

FDA Clears Magnetom Sola 1.5T MRI From Siemens Healthineers
Technology | Magnetic Resonance Imaging (MRI) | October 09, 2018
The U.S. Food and Drug Administration (FDA) has cleared the Magnetom Sola, a 1.5 Tesla magnetic resonance imaging (MRI...
ViewRay and Miami Cancer Institute Host Symposium on MR-Guided Radiation Therapy
News | Image Guided Radiation Therapy (IGRT) | October 05, 2018
October 5, 2018 — Leading oncology experts from around the world recently met to discuss the integration of...
An example of the newest generation of smart cardiac CT software that automatically identifies the anatomy, autotraces the centerlines on the entire coronary tree and labels each vessel segment.

An example of the newest generation of smart cardiac CT software that automatically identifies the anatomy, autotraces the centerlines on the entire coronary tree and labels each vessel segment. This greatly speeds CT workflows, saving time for techs, radiologists and cardiologists.

Feature | Radiology Imaging | October 04, 2018 | By Dave Fornell
Here is a checklist of dose-sparing practices for cardiac computed tomography (CT) imaging used in the cath lab.
Osprey Medical and GE Healthcare Launch Acute Kidney Injury Educational Program
News | Angiography | September 25, 2018
September 21, 2018 — Osprey Medical announced a collaboration with GE Healthcare on Osprey’s Be Kind to Kidneys campa
Turkish Hospital Begins MR-Guided Radiation Therapy With Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | September 21, 2018
ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's...
Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...